Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Generic User Fees Get Another Hearing As FDA Seeks More Public Comment

This article was originally published in The Pink Sheet Daily

Executive Summary

The agency may not feel all industry sector voices have been heard and wants to provide another opportunity for input at the May 10 session, but negotiations with GPhA and API groups are continuing.

You may also be interested in...



Generic User Fees Would Create 10-Month ANDA Review Time

Annual revenue of $250 million to $300 million in generic drug user fees is discussed as FDA unveils its "four walls and a roof" guiding principles.

Generic User Fees Would Create 10-Month ANDA Review Time

Annual revenue of $250 million to $300 million in generic drug user fees is discussed as FDA unveils its "four walls and a roof" guiding principles.

GDUFA Talks: FDA Reminds Industry The Program Is Generic-Only

Generic drug user fee negotiations began with a reminder that components of the program will not apply to other regulated drug sectors.

Related Content

Topics

UsernamePublicRestriction

Register

PS072167

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel